Payer Evidence · Health Economics · Market Access
Wamukelekile
Welcome, you all the travelers of the world. Uthando Nethemba reads clinical trials and health-policy signals closely — turning them into decision-ready notes on evidence, health economics, and market access.
Latest from the Blog
A $16K Humanoid Completed a Gallbladder Removal in a Pig — But a Human Drove Every Move
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. A UC San Diego team (Yip lab) mounted wristed laparoscopic instruments on a low-cost commercial humanoid (Unitree G1) and ran a three-stage study — benchtop characterization, dry-lab user study,…
Blocking the Clot Is Not Protecting the Brain: An Unpeer-Reviewed UK Biobank Preprint on Atrial Fibrillation and Brain Health (n=502,099)
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The paper discussed below is a medRxiv preprint (v1, posted 2026-08-12) that has not yet been peer-reviewed. It is an observational cohort analysis with Mendelian randomization as a secondary…
Mechanism-Encoded Prediction of Prime Editing: What OptiPrime’s Ablations Actually Prove, and What Remains Unconfirmed
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The Nature Biotechnology version of the paper discussed here is paywalled and was not accessed by this outlet. Everything below marked “confirmed” was verified directly against the bioRxiv preprint (submitted 2026-02-20), which the…
Get new content delivered directly to your inbox.
Uthando Nethemba 